Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com
Uproleselan Plus Chemotherapy Continues to Show Promise in AML
March 17th 2022The addition of uproleselan to standard chemotherapy improved improve response rates and reduced chemotherapy-induced mucositis in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia in a phase 1/2 trial.
Read More
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
March 11th 2022Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Read More
Phase 1/2 FELIX Trial to Determine Obe-Cel Potential in Adult Patients With ALL
March 10th 2022Claire Roddie, MD, PhD, discusses how the phase 1/2 FELIX trial could impact the treatment landscape for acute lymphoblastic leukemia, how CAR T-cell therapies have evolved, and what challenges remain in making these treatments more accessible for patients.
Read More
Eleni Efstathiou, MD, PhD, discussed the combination of niraparib and abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations, results from the MAGNITUDE trial, and next steps for research.
Read More
Bispecific Antibodies Show Potential After Relapse on CAR T-cell Therapy in Myeloma
March 2nd 2022Oliver Van Oekelen, MD, MSc, discusses findings from a retrospective study that evaluated treatment and efficacy outcomes in patients with relapsed or refractory multiple myeloma who experienced disease progression after BCMA-directed CAR T-cell therapy.
Read More
Proactive Care Is Required to Manage Belantamab Mafodotin–Associated Keratopathy in Myeloma
March 1st 2022Sarah Sunshine, MD, discusses the management of keratopathy associated with belantamab mafodotin treatment in patients with multiple myeloma and explained why ophthalmologists play a vital role in addressing these adverse effects.
Read More
ECOG-ACRIN Works to Improve Representation of Minority Populations in Cancer Clinical Trials
February 28th 2022One of the primary goals of the ECOG-ACRIN Health Equity Committee is to continue addressing disparities that limit the representation of minority populations in cancer clinical trials.
Read More
A clinical algorithm-based approach that was developed to improve fractional polynomial model selection utilized additional criteria based on face validity, predictive accuracy, and expert opinion, which improved the plausibility of survival outcomes in patients with renal cell carcinoma.
Read More
Axitinib/Pembrolizumab Shows Real-World Efficacy in Frontline Advanced RCC
February 27th 2022A real-world analysis showed that patients with advanced renal cell carcinoma in the United States who received the combination of axitinib and pembrolizumab derived similar efficacy with the regimen as those who had received it in randomized clinical trials.
Read More
MRD-Guided Treatment Approach Generates Excitement in Stage II to III Colon Cancer
February 22nd 2022The utilization of a circulating tumor DNA assay to detect the presence of minimal residual disease may provide an opportunity to better inform treatment decisions in patients with early-stage colon cancer.
Read More
Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.
Read More
Cabozantinib/Atezolizumab Combo Demonstrates Promising Clinical Activity in mCRC
February 18th 2022Thomas A. Abrams, MD, discusses the ongoing phase 1b COSMIC-021 trial examining cabozantinib/atezolizumab, the efficacy and safety demonstrated with the regimen in those with colorectal cancer, and the next steps for research
Read More
Pelabresib Monotherapy Shows Benefit in JAK Inhibitor–Naïve Advanced Myelofibrosis
February 17th 2022Marina Kremyanskaya, MD, PhD, discusses the safety and efficacy of pelabresib in patients with myelofibrosis, additional data from the MANIFEST trial, and other efforts investigating the agent in this disease.
Read More
Eroglu Examines the Clinical Utility of ctDNA as an Emerging Biomarker for Melanoma Treatment
February 16th 2022Zeynep Eroglu, MD, discusses the potential of ctDNA as a noninvasive biomarker in melanoma, outlines different assays under development, and details potential opportunities to leverage ctDNA in treatment decision making.
Read More
Novel CAR T-cell Therapy Obe-cel Under Exploration in Relapsed/Refractory B-Cell ALL
February 15th 2022The safety and efficacy of the CD19-targeted CAR T-cell therapy obecabtagene autoleucel in the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia as part of the phase 1/2 FELIX trial.
Read More
Afami-cel Shows Clinical Benefit in Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
February 7th 2022Brian A. Van Tine, MD, PhD, sheds light on the promise of SPEAR T-cell therapy in patients with synovial sarcoma and MRCLS, the safety and efficacy observed with afami-cel in the SPEARHEAD-1 trial, and next steps for research.
Read More
Acalabrutinib Shows Better Safety, Tolerability Than Ibrutinib in Relapsed/Refractory CLL
February 4th 2022John Seymour, MD, discusses the safety of acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia, and what findings from post-hoc analyses of the ELEVATE-RR trial mean for clinical practice.
Read More
Tagraxofusp and Hyper-CVAD Represent Treatment Options for Patients with BPDCN
February 3rd 2022Naveen Pemmaraju, MD, discusses results from a retrospective study examining the utilization hyper-CVAD, and long-term follow-up data regarding the use of tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm.
Read More
Ramucirumab/Pembrolizumab Produces Encouraging ORR in Recurrent or Metastatic HNSCC
January 17th 2022The addition of ramucirumab to pembrolizumab elicited an encouraging response rate when used in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
Read More